 Most of these methods have targeted the CDK1 subunit, but there is an emerging interest in the oncology field to target cyclin B as well.Cyclin levels can easily be determined through immunohistological analysis of tumor biopsies.The fact that cyclin B is often disregulated in cancer cells makes cyclin B an attractive biomarker.